Dr Sujay Singh: Founder, President and CEO of Sujan Biologics. Sujan Biologics is developing several biosimilar antibodies, such as, Trastuzumab (herceptin), Adalimumab (humira), Bevacizuma (avastin), Ustekinumab (stellara), and Nivolumab (opdivo).Dr. Singh has more than 30 years of experience in the biotechnology field. He has a Ph.D. in Immunogenetics from the Max-Planck Institute, Germany. He had spent 11 years in academia, 10 months as a visiting scientist at Genentech before joining as Director of Cell and Molecular Biology at PharMingen, San Diego, CA. Soon after merger of PharMingen with Becton Dickenson, a fortune 500 company, Dr. Singh founded IMGENEX Corporation in 1997, which was sold to Novus Biologicals in 2013. Dr Singh’s vision is to establish a company whose mission is not only to develop high quality biomedical research tools for the characterization of these genes but also, through the discovery of novel therapeutically important genes, to develop indications for treatment of diseases. He also started IMGENEX India Pvt. Ltd., Bhubaneswar, Odisha in 2004 to provide affordable and high quality research tools to Indian scientist. IMGENEX India is a recipient of several grants from the Department of Biotechnogy, India to develop nanotechnology based treatment of osteoporosis, to develop induced pluripotent stem cells, and to develop improved mammalian expression vector for production of therapeutic antibodies and recombinant proteins. He has over 60 papers in peer-reviewed journals and 3 US patents.IMGENEX India had received Emerging Company in the Asia-Pacific Region in the year 2011 and Emerging Company of the Year 2015 in Bioindustry sector in India.
Sujan Biologics, Inc.
-
CeoSujan Biologics, Inc. Oct 2013 - PresentSan Diego, Ca 92121Sujan Biologics' goal is to develop biologic drugs against diseases caused by inflammation, such as, arthritis, psoriasis, and certain cancers. In collaboration with IMGENEX India Pvt. Ltd., Sujan Biologics is developing several biosimilar antibodies, such as, Trastuzumab (herceptin), Adalimumab (humira), Bevacizuma (avastin), Ustekinumab (stellara), and Nivolumab (opdivo).Sujan Biologics is also developing some novel bispecific antibodies for the treatment of psoriasis.
-
CeoImgenex India Pvt. Ltd. 2004 - PresentBhubaneswar, Odisha, IndiaIMGENEX INDIA Pvt. Ltd., is one of the foremost biotechnology company in the Eastern region of India and was founded by Dr. Sujay Singh, Ph.D., in the year 2004 at Bhubaneswar. IMGENEX India has built a state-of-the-art R&D facility at the Infocity complex. The R&D unit of IMGENEX India was inaugurated in 2005 by Dr. APJ Abdul Kalam, the then Hon’ble President of India and is recognized by the Department of Science and Industrial Research (DSIR), Ministry of Science & Technology, Govt. of India. The R&D Unit of IMGENEX India possesses all the modern equipment for molecular biology, recombinant protein production, cell culture, antibody development and other downstream processes. The main goal of IMGENEX India is to provide affordable healthcare to less privileged patients. Over the years IMGENEX India has received several grants from the Department of Biotechnology (DBT) that includes SIBRI grant from to develop drugs for osteoporosis using nanotechnology based drug delivery. It is in the early development phase. In addition to this with grants from BIRAC we have developed a high-yield mammalian expression system in CHO cells that is capable of producing 3-4 g per liter biosimilar Trastuzumab/Herceptin. We hoped to start clinical trial for biosimilar heceptin in the year 2019. Other biosimilars in the pipeline includes Adalimumab (humira), Bevacizuma (avastin), Ustekinumab (stellara), and Nivolumab (opdivo).
-
CeoImgenex Corporation Jul 1997 - Oct 2013San Diego, CaFounded IMGENEX Corporation in 1997 to develop high quality research tools including monoclonal antibodies, ELISA kits, siRNAs, and tissue microarrays for biomedical research. IMGENEX was sold to Novus Biologicals in 2013.
-
Director, Cell BiologyPharmingen Nov 1992 - Jul 1997San Diego, CaSupervising a group of scientists for development and characterization of monoclonal antibodies against proteins involved in signal transduction, apoptosis, neurotransmission, and infectious diseases, etc. Working with the marketing group, helped commercialization of these antibodies and other reagents for biomedical research.
Sujay Singh Skills
Sujay Singh Education Details
-
Max-Planck Institute, Tuebingen, GermanyMicrobiological Sciences And Immunology
Frequently Asked Questions about Sujay Singh
What company does Sujay Singh work for?
Sujay Singh works for Sujan Biologics, Inc.
What is Sujay Singh's role at the current company?
Sujay Singh's current role is CEO.
What schools did Sujay Singh attend?
Sujay Singh attended Max-Planck Institute, Tuebingen, Germany.
What skills is Sujay Singh known for?
Sujay Singh has skills like Molecular Biology, Biotechnology, Biochemistry, Immunology, Technology Transfer, Life Sciences, Cell Culture, Cell Biology, Commercialization, Drug Discovery.
Not the Sujay Singh you were looking for?
-
3gmail.com, atomicstaffing.com, wellsfargo.com4 +140862XXXXX
-
SUJAY SINGH
Graduate Student At The University Of Texas At Dallas | Ms In Business Analytics| Ex Data Analyst At Konigtronics Pvt Ltd| Actively Seeking Internship For Summer 2024Dallas-Fort Worth Metroplex -
-
1yahoo.com
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial